About this trial
This pilot study aims to evaluate the feasibility and acceptability of nocturnal translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two months in patients with Parkinson's Disease.
Eligibility criteria
Qualifiers
Informed Consent signed by the subject
PD according to the MDS clinical diagnostic criteria for Parkinson's disease
Suffering from reduced sleep quality as defined by pathological cut-off (score of > 5) on the Pittsburgh Sleep Quality Index (PSQI)
Patients with stable antiparkinsonian, antidepressant, and sleep medications for six weeks before intervention and maintained on stable medication during the intervention period
Disqualifiers
Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).
Dementia as defined by a MOCA score lower than 24/30
Weight > 150kg
Depression with acute suicidal ideation
Trial design
Treatments tested in this trial
- Nocturnal translational vestibular stimulation
Treatment groups
Sponsors and collaborators
Insel Gruppe AG, University Hospital Bern
Lead sponsor
ETH Zurich
Collaborator